|
Originally published In Press as doi:10.1074/jbc.M201427200 on August 2, 2002
J. Biol. Chem., Vol. 277, Issue 41, 38254-38261, October 11, 2002
p38 Mitogen-activated Protein Kinase Regulates
Interleukin-4-induced Gene Expression by Stimulating
STAT6-mediated Transcription*
Marko
Pesu §,
Saara
Aittomäki ,
Kati
Takaluoma ,
Anssi
Lagerstedt¶, and
Olli
Silvennoinen §
From the Institute of Medical Technology, University
of Tampere, FIN-33014 Tampere, Finland, the § Department
of Clinical Microbiology, Tampere University Hospital, FIN-33521
Tampere, Finland, and the ¶ Department of Pathology,
University of Tampere, FIN-33014 Tampere, Finland
Received for publication, February 12, 2002, and in revised form, July 31, 2002
 |
ABSTRACT |
STAT6 functions as a critical mediator of
IL-4-stimulated gene activation, and the function of STAT6 is regulated
by both tyrosine and serine kinase activities. Here we analyzed the
role of serine phosphorylation in regulation of STAT6-mediated
transcription. Optimal transcriptional response of IL-4-inducible
promoters requires costimulatory signals through CD40-stimulated
intracellular kinases such as p38 MAPK. We found that the p38 MAPK
inhibitor SB202190 as well as the dominant negative p38 MAPK inhibited
interleukin (IL)-4 regulated expression of CD23 in Ramos B cells. IL-4
stimulation did not stimulate p38 MAPK activity, but inhibition of p38
MAPK activity directly correlated with inhibition of IL-4-induced gene activation. Dissection of individual response elements on
IL-4-regulated promoter showed that C/EBP -mediated transcription was
insensitive to SB202190 treatment in B cells whereas STAT6-mediated
transcription was regulated by p38 MAPK. The IL-4-induced immediate
activation events of STAT6 were not affected by p38 MAPK activity.
Furthermore, phosphoamino acid analysis and phosphopeptide mapping
indicated that STAT6 is not a direct substrate for p38 MAPK. Instead,
p38 MAPK was found to directly regulate the activity of the
transactivation domain of STAT6. These results show that, in addition
to the well established proinflammatory effects, p38 MAPK also provides
a costimulatory signal for IL-4-induced gene responses by directly stimulating the transcriptional activation of STAT6.
 |
INTRODUCTION |
Interleukin-4 (IL-4)1 is
a pleiotropic cytokine, which has an important function in regulation
of Th2 cells and B cells during humoral immune responses. Optimal
activation of B cells is dependent on two Th2-mediated stimuli, IL-4
and a second signal provided by CD40 ligand (CD40L) (1). IL-4, together
with CD40-mediated signals, stimulate the proliferation of B cells, and
induce the expression of the low-affinity Fc receptor for IgE (CD23),
major histocompatibility complex class II molecules, and
stimulate the transcription of unrearranged immunoglobulin heavy-chain
germline Ig and Ig 1 genes leading to class switching and IgE and
IgG1 synthesis (2, 3).
The biological functions of IL-4 are mediated through the IL-4 receptor
(IL-4R) complex that activates the Jak1 and Jak3 tyrosine kinases
leading to intracellular signal transduction (2). STAT6 functions as a
crucial mediator of IL-4-specific gene responses, as attested by the
similar phenotypes of the STAT6 and IL-4 knock-out mice presenting
deficient Th2 differentiation and absence of IgE responses (4, 5).
Recruitment of STAT6 to the tyrosine-phosphorylated IL-4 receptor
-chain initiates the activation cascade, and in the receptor complex
STAT6 becomes phosphorylated on its C-terminal tyrosine residue by the
Jak kinases. Tyrosine phosphorylation causes STAT6 to dimerize and
translocate to the nucleus where it binds to specific DNA elements on
IL-4 responsive genes (2).
The promoter regions of IL-4 inducible genes contain several
cis-acting elements and the cooperation between different
transcription factors is critical for efficient regulation of gene
transcription. For example, the promoters of human CD23 and Ig genes
contain in addition to STAT6-binding sites, also response elements for CCAAT/enhancer-binding protein (C/EBP ) NF- B, interferon
regulatory factor-4, and B cell-specific activator protein (Pax5) (6, 7). STAT6 appears to be the only transcription factor that is
functionally regulated by IL-4, whereas the other factors are either
regulated by costimulatory signals as exemplified by CD40-mediated regulation of NF- B or through transcriptional regulation (8, 9).
STAT6 has been shown to cooperate with several
transcription factors, but the mechanisms of cooperation between
various transcription factors differ significantly. For example,
C/EBP stabilizes the DNA binding of STAT6, whereas the effects of
interferon regulatory factor-4 and NF- B are directed to
transcriptional activation and involve physical interaction with STAT6
(7, 10, 11).
STAT-mediated gene responses are modulated by additional signaling
pathways, which provide important diversity and additional regulation
to the biological effects of cytokines. It has become evident that
STATs are subject to post-translational modification through serine
phosphorylation. STAT1, STAT3, STAT4, STAT5, and STAT6 have been shown
to be phosphorylated on serine residues in their transactivation domain
(TAD) in response to various stimuli (12-14). The functional
consequence of the serine phosphorylation modification is best
characterized in STAT1 where phosphorylation of Ser-727 regulates the
interaction with BRCA1 and mini-chromosome maintenance 5 coactivator
and affects the specificity of target gene expression (15-17).
The serine-phosphorylation sites of STAT1, STAT3, and STAT4 contain a
conserved PMSP or PSP motif that confers the consensus mitogen-activated protein (MAP) kinase phosphorylation site, and thereby the role of MAP family kinases in regulation of STAT
phosphorylation has been extensively studied. Extracellular
signal-regulated kinases (ERK) are mediating the serine phosphorylation
of STAT3 upon epidermal growth factor stimulation but ERKs are not
involved in cytokine-induced phosphorylation of STATs (18). Recently,
much attention has been focused on the role of p38 MAPK in the
regulation of STATs. p38 MAPK has been shown to mediate the
lipopolysaccharide and cellular stress-induced phosphorylation
of Ser-727 in STAT1, and the IL-12-induced phosphorylation
of Ser-721 of STAT4 (19, 20). Furthermore, p38 MAPK kinase activity is
required for optimal STAT1-mediated transactivation of interferon
-activated site and interferon-stimulated response element promoters
without an effect on IFN -induced phosphorylation of Ser-727 of STAT1
(21, 22). The IL-6-induced transcriptional activation of STAT3 has also
been shown to be dependent on IL-6-stimulated p38 MAPK activity in
hepatocytes (23).
We have recently shown that STAT6-mediated gene activation is regulated
through as yet unidentified serine kinase(s) (13). Engagement of CD40
surface antigen leads to rapid activation of several tyrosine and
serine/threonine kinases (24-26), and provides costimulatory signals
for STAT6-mediated transcription. p38 MAPK is readily activated through
CD40, and thereby we wanted to analyze the role of p38 MAPK in
IL-4-induced transcription. Our results indicate a direct role for p38
MAPK in regulation of STAT6-mediated transcriptional activation.
 |
EXPERIMENTAL PROCEDURES |
Cell Culture and Transfections--
All the cell lines were
obtained from American Type Culture Collection, Manassas, VA. HepG2
cells were grown in Dulbecco's modified Eagle's medium supplemented
with 10% fetal bovine serum (Invitrogen) and antibiotics. Daudi
and Ramos 2g6 B cells were grown in RPMI medium (Invitrogen) containing
10% fetal bovine serum and antibiotics. Transfections of HepG2 cells
were done by the calcium phosphate coprecipitation method. Daudi cells
were electroporated with a Bio-Rad gene pulser at 220 V/960 µF. For some experiments Daudi cells were also transfected with DEAE-dextran as
previously described (27). Ramos cells were transfected with 40 µg of
plasmid DNA by electroporation at 200 V/960 µF (28).
Antibodies--
-Phosphotyrosine antibody (clone 4G10) was
from Upstate Biotechnology (Lake Placid, NY) and mouse monoclonal
antibody against human CD40 was from Immunotech (Marseille, France).
-STAT6 (M-20), -p38 (N-20), and -C/EBP (C-19) antibodies
were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA).
-Phosho-p38 antibody was from New England Biolabs Inc. (Beverly, MA).
Immunoprecipitation and Western Blotting--
Cells were lysed
in Triton lysis buffer (50 mM Tris-HCl, pH 7.5, 10%
glycerol, 150 mM NaCl, 1 mM EDTA, 1% Triton
X-100, 50 mM NaF, 1 mM
Na3VO4), supplemented with phenylmethylsulfonyl
fluoride and aprotinin, and immunoprecipitations from equal protein
amounts were carried out as previously described (29). Protein
concentrations of the lysates were measured using the Bio-Rad protein
assay system. Immunoprecipitates were separated by SDS-PAGE and
transferred onto nitrocellulose membrane (Micron Separation Inc.,
Westborough, MA). Immunodetection was performed using specific primary
antibodies, biotinylated anti-mouse or anti-rabbit secondary antibodies
(Dako A/S, Denmark), and streptavidin-biotin horseradish
peroxidase-conjugate and ECL detection (Amersham Biosciences).
Electrophoretic Gel Mobility Shift Assay--
For the
electrophoretic gel mobility shift assay Daudi B cells were lysed in
whole cell extract lysis buffer (29). Annealed Ig oligonucleotide
(13) (5'-CGATCAAGACCTTTCCCAAGAAATCT-3') was end-labeled by T4
polynucleotide kinase using [ -32P]ATP. Reactions were
performed as previously described (29) and resolved in 4.5% TBE
(2.2×) PAGE, followed by autoradiography.
DNA Constructs--
Construction of C/EBP -STAT6-RE and
C/EBP -RE reporter plasmids has been described earlier (13). STAT6-RE
was created by cloning annealed oligonucleotides (STAT6-RE
5'-p-TCGACGACTTCCCAAGAACAGCGACTTCCCAAGAACAGCGACTTCCCAAGAACG-3' and
5'-p-TCGACTGTTCTTGGGAAGTCGCTGTTCTTGGGAAGTCGCTGTTCTTGGGAAGTCG-3') into the SalI site of pfLUC-plasmid containing
c-fos minimal promoter in front of the Photinus
pyralis luciferase gene. GAL4-RE reporter plasmid and
GAL4-STAT6TAD (amino acids from 642 to 847) were kind gifts from Dr. B. Groner (30). Dr. Tuula Kallunki kindly provided the
hemagglutinin-tagged p38 MAPK expression plasmid. The dominant negative p38 MAPK (p38AF) and constitutively active MKK6b (MKK6b(E)) (31) were kindly provided by Dr. J. Han. pCMV- -galactosidase plasmid
for HepG2 cells and elongation factor promoter-driven pEBB- -galactosidase plasmid (47) for Daudi cells were used to
monitor transfection efficiency.
Luciferase Assay--
HepG2 cells were transfected on 6-well
plates by the calcium phosphate coprecipitation method and Daudi cells
by DEAE-dextran or by electroporation as described above. Cells were
grown for 24-48 h and starved overnight in medium containing 1% fetal
bovine serum. After starvation the concentration of Daudi cells was
adjusted to 1 × 106 cells per ml. Cells were
stimulated with 10 ng/ml recombinant human IL-4 (PeproTech EC Ltd.,
London, United Kingdom) or 1 µg/ml -human CD40-antibody
(Immunotech). p38 MAPK inhibitor (SB202190) (Sigma) was added to the
cultures 60 min before stimuli when indicated. After stimulation for
6-16 h cells were lysed in reporter lysis buffer (Promega, Madison,
WI) and luciferase activity was determined using the luciferase assay
system (Promega) according to manufacturer's instructions. The
luciferase values were normalized against measured -galactosidase
activities or against total protein concentration in Daudi cells when
the DEAE-dextran method was used for transfection.
Phosphoamino Acid Analysis and Phosphopeptide
Map--
Phosphoamino acid analysis and phosphopeptide maps were done
as described earlier (32). Briefly, Daudi cells were starved overnight
and labeled with [32P]orthophosphate (Amersham
Biosciences) in phosphate-free medium (Sigma) for 3 h. Cells were
stimulated as indicated and lysed in Triton lysis buffer, and STAT6 was
immunoprecipitated. Immunocomplexes were separated on SDS-PAGE and
transferred onto nitrocellulose membrane. Proteins were visualized by
autoradiography and bands corresponding to STAT6 were excised for
further analysis. For the phosphopeptide map, proteins were digested
with sequencing grade trypsin (Promega). Washed fragments were applied
to thin layer cellulose plates, separated in the first dimension by
electrophoresis at pH 1.9 and in the second dimension by ascending
chromatography using isobutyric acid buffer (isobutyric
acid:1-butanol:pyridine:acetic acid:water, 1250:38:96:58:558,
v/v/v/v/v/v). Phosphopeptides were visualized by autoradiography. For
the phosphoamino acid analysis ~10% of the digested proteins were
hydrolyzed in HCl for 1 h at 110 °C. Lysates were lyophilized
and resolved in pH 1.9 buffer containing standard phosphoamino acids
(o-phospho-DL-serine,
o-phospho-DL-threonine, o-phospho-DL-tyrosine from Sigma).
Phosphoamino acids were separated by two-dimensional electrophoresis.
Standard amino acids were visualized by ninhydrin staining and
autoradiography was used to detect phosphorylated amino acids.
FACS Analysis--
Ramos B cells were suspended in RPMI + 10%
fetal bovine serum and stained for 30 min at 4 °C with 20 µl of
fluorescein isothiocyanate-conjugated mouse -human-CD23 antibody
(Pharmingen, San Diego, CA) or with 20 µl of PE-conjugated mouse
-human-CD23 antibody (BD Biosciences). Unspecific staining
was monitored with isotype-matched control antibodies, fluorescein
isothiocyanate-conjugated mouse -human-CD64 antibody (Immunotech,
Marseille, France) and PE-conjugated mouse -human-CD13 antibody (BD
Biosciences). Cells were washed twice with phosphate-buffered saline
and analyzed with FACScan (BD Biosciences).
 |
RESULTS |
p38 Mitogen-activated Protein Kinase Activity Is Required for
Stimulation of CD23 Expression in Ramos B Cells--
We have
previously shown that STAT6-mediated transcription is regulated by
Ser/Thr kinases (13). CD40 cell surface molecules mediate important
costimulatory signals for IL-4-induced gene responses (33, 34), and
activate protein kinases including p38 MAPK (24-26). These findings
together with recent results about the role of p38 MAPK in regulation
of cytokine signaling led us to investigate the role of p38 MAPK in
IL-4-induced gene activation. We first tested the effect of p38 MAPK
inhibitors on IL-4/CD40-induced expression of CD23 on highly
IL-4-responsive Ramos 2g6 B cells. Cell-permeable pyridinyl imidazole
compounds SB202190 and SB203580 are specific inhibitors of and isoforms of p38 MAPK and they do not inhibit kinase activity of other
mitogen-activated protein kinases such as ERKs and c-Jun
NH2-terminal kinases (35).
Ramos B cells were stimulated for 20 h with IL-4 in the presence
or absence of different concentrations of SB202190, and the surface
expression of CD23 was measured with FACScan. IL-4 stimulation resulted
in robust induction of CD23 expression (Table
I, A). -CD40 treatment alone did not
increase CD23 expression, but further enhanced the IL-4-induced CD23
expression. B cells express low levels of CD23 without any apparent
stimulation, and SB202190 inhibited both the basal and the induced
expression of CD23 in a dose-dependent manner. Inhibition
was evident already at 1 µM concentration of SB202190.
The inhibitor did not affect the viability of Ramos B cells at any
concentration used.
View this table:
[in this window]
[in a new window]
|
Table I
p38 MAPK kinase activity is required for CD23 expression in Ramos
2g6 B cells
(A) Ramos B cells were left untreated or treated with IL-4 (10 ng/mL)
and/or -CD40 antibody (1 mg/ml) for 20 h in the absence or
presence of different concentrations of p38 MAPK inhibitor SB202190.
(B) Ramos B cells were transfected by electroporation with the dominant
negative p38 MAPK (p38AF) or with empty vector (pSG5) and treated
with IL-4 and -CD40 antibody as in A. CD23 expression was analyzed
by staining with fluorescein isothiocyanate-conjugated (A) or
PE-conjugated (B) -CD23 mABs. Fluorescence intensity was determined
using FACScan, and the mean fluorescence intensities (MFI) are shown.
MFI for isotype matched fluorescein isothiocyanate-conjugated negative
control antibody was 5.6 and for PE-conjugated negative control
antibody 4.0. Experiments were repeated three times with identical
results.
|
|
The role of p38 MAPK in regulation of CD23 expression was further
investigated by using the dominant negative form of p38 MAPK . Ramos
B cells were transfected with the dominant negative p38 MAPK (p38AF)
or empty vector (pSG5), and the CD23 expression was analyzed by FACScan
using PE-conjugated -CD23 antibody. Despite the low transfection
efficiency in Ramos cells, the ectopic expression of p38AF resulted in
25-35% inhibition of CD23 expression in three independent experiments
(Table I, B).
These results suggested that p38 MAPK activity is regulating CD23
expression. However, the enhancing effect of CD40 ligation on
IL-4-induced CD23 expression was rather modest, and next we analyzed
the effect of IL-4 stimulation and CD40 engagement on p38 MAPK
activation in B cells directly. Ramos 2g6 and Daudi B cells were
pretreated with SB202190 or with vehicle before IL-4 and/or -CD40
were added to the cultures for different times. Cell lysates were
subjected to Western blotting with -phospho-p38 MAPK antibody, which
is specific for the
Thr180/Tyr182-phosphorylated catalytically
active form of p38 MAPK. Constitutive phosphorylation of p38 MAPK was
readily detected in both Daudi and Ramos cells (Fig.
1). IL-4 stimulation (5 min to 24 h)
did not activate p38 MAPK in any of the cell lines tested (Daudi, Ramos, HepG2, HeLa, and 293T) (Fig. 1, and data not shown).
In Daudi cells cross-linking of CD40 resulted in rapid induction and
prolonged activation (at least up to 6 h, Fig. 1B) of
p38 MAPK, whereas in Ramos cells CD40 engagement only slightly
increased (10-20%) p38 MAPK activity (Fig. 1B). SB202190
pretreatment markedly diminished the basal phosphorylation of p38 MAPK
as well as the CD40-induced phosphorylation in both cell lines. Thus,
in Ramos cells, CD23 expression directly correlated with the level of
p38 MAPK activation (high basal activity, low -CD40 induction).

View larger version (33K):
[in this window]
[in a new window]
|
Fig. 1.
The effect of IL-4 and
-CD40 on phosphorylation of p38 MAPK in Ramos and
Daudi B cells. Cells were serum-depleted overnight and left
untreated or pretreated with SB202190 (20 µM) for 60 min.
IL-4 (100 ng/ml) and -CD40 antibody (1 µg/µl) were added to
cultures for 5 or 15 min (A) or 6 h (B) as
indicated. Cells were lysed in Triton X-lysis buffer and 20 µg of
total cell lysate were separated on 10% SDS-PAGE. Proteins were
transferred onto nitrocellulose filter, which was probed with
-phospho-p38 MAPK antibody. In the lower panels are shown
the same filters probed with p38 MAPK antibody.
|
|
IL-4/CD40-induced Activation of
STAT6-dependent Reporter Gene Constructs from Ig
Promoter Is Dependent on p38 MAPK Activity--
The IL-4-responsive
promoter regions of human Ig and CD23 genes contain binding elements
for several transcription factors such as C/EBP , STAT6, NF- B, and
B cell-specific activator protein (6). To define the target element for
p38 MAPK activity, we created reporter constructs from human Ig
promoter encompassing different response elements (RE) (C/EBP -RE,
STAT6-RE, C/EBP -STAT6-RE, C/EBP -STAT6-NF- B-RE, and
STAT6-NF- B-RE). The effect of SB202190 treatment on various reporter
constructs was analyzed in Daudi B cells after IL-4/CD40 stimulation.
Daudi cells do not express CD23 but they were chosen for
reporter gene studies because of their CD40-regulated p38 MAPK
activation and relatively good transfection efficiency. Previously CD40
has been shown to stimulate NF- B-dependent transcriptional responses through p38 MAPK activation (8, 36). However,
in our experiments SB202190 inhibited the IL-4-induced reporter
activity also in the absence of the NF- B response element (data not
shown). Thereby we wanted to investigate in more detail the role of
p38 MAPK in activation of the minimal IL-4 response element.
IL-4 induced the activity of the C/EBP -STAT6-RE reporter in Daudi
cells (Fig. 2A). The
IL-4-induced activity was further stimulated via CD40 antigen, but CD40
signal alone did not induce any reporter activity. Pretreatment of
Daudi cells with SB202190 inhibited both IL-4 and IL-4+ -CD40
enhanced reporter activities to the same extent. Similar inhibition was
observed with another p38 MAPK inhibitor SB203580 (data not
shown). Furthermore, the p38 MAPK inhibitor was found to
decrease the IL-4-induced C/EBP -STAT6-RE reporter activity also in
nonhematopoietic HepG2 cells in a dose-dependent manner
(data not shown).

View larger version (12K):
[in this window]
[in a new window]
|
Fig. 2.
p38 MAPK kinase activity is required
for IL-4/CD40-induced activation of
C/EBP -STAT6-RE reporter construct.
A, Daudi B cells were transfected with the C/EBP -STAT6-RE
reporter construct (10 µg for 1 × 107 cells) by the
DEAE-dextran method. Forty-eight hours after transfection
overnight-starved cells were left untreated or pretreated with SB202190
(20 µM) for 60 min and stimulated with IL-4 (10 ng/ml)
and -CD40 antibody (1 µg/µl) for 6 h. Measured luciferase
values were normalized against total protein concentrations and are
shown as relative luciferase units (RLU). B,
Daudi cells were transfected by electroporation with the
C/EBP -STAT6-RE reporter construct (8.0 µg) together with the
EBB- -galactosidase construct (8.0 µg) and 12 µg of dominant
negative p38 MAPK (p38AF) or pSG5 plasmid DNA (sg5) as indicated.
Twenty-four hours after transfection cells were starved and stimulated
overnight with IL-4 and -CD40. Luciferase activities were normalized
against -galactosidase values. The RLUs of pSG5 transfected and
IL-4-stimulated cells were given an arbitrary value of 100, and the
other values are shown in proportion to this as percentage of activity
(%). C, Daudi B cells were transfected by electroporation
with the C/EBP -STAT6-RE reporter construct together with
EBB- -galactosidase and p38 MAPK wt (4.0 µg) or pSG5 plasmids.
Cells were starved overnight and pretreated with SB202190 (10 µM) when indicated and stimulated as in A. The
RLUs of pSG5 transfected and IL-4 stimulated cells were given an
arbitrary value of 100, and the other values are shown in proportion to
this as percentage of activity (%). The means of three to six
independent experiments with standard deviations are shown.
|
|
To exclude the possibility that SB202190 would inhibit the
IL-4-stimulated transcription by an unspecific, p38 MAPK-independent way, we studied the effect of overexpression of both dominant negative
and wild type p38 MAPK (p38AF and p38wt, respectively) in Daudi
cells (Fig. 2, B and C). Overexpression of p38
MAPK resulted in activation of the kinase as detected by Western
blotting with phospho-p38 MAPK-specific antibody and in autokinase
assay (data not shown). As expected, the ectopic expression of
p38AF reduced and p38wt enhanced both IL-4- and IL-4+ -CD40-induced gene activation in Daudi cells (Fig. 2, B and C).
The inhibitory effect of SB202190 (10 µM) was observed
also in the p38wt-transfected Daudi B cells (Fig. 2C).
In HepG2 cells the C/EBP -STAT6 region in the human Ig promoter
has been shown to be the minimal IL-4 response element (37). To analyze
the individual roles of these transcription factors, reporter
constructs consisting of only C/EBP -RE or STAT6-RE were utilized.
C/EBP -RE reporter was found to be constitutively active in both
Daudi (Fig. 3A) and HepG2
cells (data not shown). Overexpression of p38 MAPK did not stimulate
the activity of C/EBP -RE in HepG2 cells (data not shown), and in
Daudi cells SB202190 treatment did not reduce the activity of the
C/EBP -RE reporter construct (Fig. 3A). The activity of
C/EBP is regulated by p38 MAPK-induced serine phosphorylation in
mouse hepatocytes (38). We analyzed the effects of IL-4 and -CD40
stimulation, in the presence or absence of SB202190, on the total
phosphorylation of C/EBP in B cells. Endogenous C/EBP was
constitutively phosphorylated in Daudi B cells but no changes on
phosphorylation of C/EBP were observed in response to any of the
treatments (data not shown).

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 3.
SB202190 inhibits the IL-4 and IL-4/CD40
induced activity of STAT6-dependent but not the
constitutive activity of
C/EBP -dependent reporter.
Daudi B cells were transfected with C/EBP -RE (A) or
STAT6-RE (B) reporter constructs (10 µg for 1 × 107 cells) by the DEAE-dextran method. Forty-eight hours
after transfection overnight-starved cells were left untreated or
pretreated with SB202190 (20 µM) for 60 min and
stimulated with IL-4 (10 ng/ml) and -CD40 antibody (1 µg/µl) as
indicated. After 6 h cells were lysed and luciferase activities
and protein concentrations were measured. The luciferase values were
normalized against total protein concentrations. The means of three
independent experiments with standard deviations are shown.
|
|
The reporter construct that consists of binding sites only for STAT6 is
not functional in HepG2 cells (37) (data not shown). However, in Daudi
B cells the STAT6-RE functioned similarly as the C/EBP -STAT6-RE, and
the STAT6-RE reporter was activated by IL-4 and the activity was
further enhanced via CD40 (Figs. 2A and 3B). The
IL-4 and IL-4+ -CD40-induced activities of STAT6-RE were sensitive to
SB202190 treatment. In conclusion, these results suggest that the
target for p38 MAPK activity is on STAT6-mediated transcription.
STAT6 Is Not Phosphorylated by p38 MAPK--
To analyze the
mechanism of p38 MAPK-mediated regulation of STAT6 activation in more
detail, we studied the effect of SB202190 on tyrosine phosphorylation
and DNA binding of STAT6 in Daudi B cells. IL-4 stimulation caused
rapid tyrosine phosphorylation and DNA binding of STAT6 (Fig.
4, A and B),
whereas CD40 engagement alone did not activate STAT6. Pretreatment of
the cells with SB202190 had no effect on the immediate activation
events of STAT6 for up to 2 h (Fig. 4, A and
B, and data not shown).

View larger version (37K):
[in this window]
[in a new window]
|
Fig. 4.
SB202190 does not affect the IL-4-induced DNA
binding and tyrosine phosphorylation of STAT6 in Daudi B cells.
Overnight-starved Daudi B cells were left untreated or pretreated with
SB202190 (20 µM) for 1 h and stimulated with IL-4
(100 ng/ml) and -CD40 (1 µg/ml) for 20 min as indicated. For
mobility shift assay (A) cells were lysed in whole cell
extract lysis buffer and electrophoretic mobility shift assay reactions
were performed using the 32P-labeled Ig oligonucleotide
probe. The STAT6 binding complex is indicated with an arrow.
For Western blotting (B) cells were lysed in Triton-X lysis
buffer. STAT6 was immunoprecipitated and separated by 7.5% SDS-PAGE
and proteins were transferred onto nitrocellulose filter. The
upper panel shows -phosphotyrosine (pTyr)
immunoblotting. STAT6 protein levels were immunoblotted from 20 µg of
total cell lysates (lower panel).
|
|
Previously we showed that STAT6 is subject to both constitutive and
IL-4-induced serine phosphorylation (13). To investigate the possible
role of p38 MAPK on phosphorylation of STAT6, overnight starved Daudi B
cells were metabolically labeled with [32P]orthophosphate
for 3 h in the presence or absence of SB202190. Cells were
stimulated with IL-4 and/or -CD40 for 20 min, and STAT6 was
immunoprecipitated and separated on SDS-PAGE. Proteins were transferred
onto nitrocellulose filter and visualized by autoradiography. IL-4
stimulation induced phosphorylation of STAT6, which was not affected by
SB202190 treatment. -CD40 treatment did not have any effect on total
phosphorylation of STAT6 (Fig. 5A). The band corresponding to
STAT6 was excised and phosphorylation events were further studied in
phosphoamino acid analysis and phosphopeptide mapping.

View larger version (64K):
[in this window]
[in a new window]
|
Fig. 5.
SB202190 does not inhibit IL-4-induced
phosphorylation of STAT6. Daudi B cells were starved overnight and
metabolically labeled with [32P]orthophosphate in
phosphate-free medium for 3 h in the absence or presence of
SB202190 (20 µM). Cells were stimulated with IL-4 (100 ng/ml) and -CD40 (1 µg/ml) for 20 min as indicated. Cells were
lysed in Triton-X lysis buffer and STAT6 was immunoprecipitated.
Immunocomplexes were separated on 7.5% SDS-PAGE and transferred to
nitrocellulose filter. A, autoradiography of the
precipitates, STAT6 is indicated with an arrow.
B, phosphoamino acid analysis of the excised and hydrolyzed
STAT6 bands. PS, PT, and PY areas
indicate the positions of phosphoserine, phosphothreonine, and
phosphotyrosine, respectively. For the phosphopeptide map
(B) the STAT6 proteins were digested with trypsin. Fragments
were separated in the first dimension by electrophoresis at pH 1.9 and
in the second dimension by ascending chromatography. Phosphopeptides
visualized by autoradiography are shown. X indicates origin
of electrophoresis. The panels A, B, and
C are derived from the same experiment.
|
|
In unstimulated cells STAT6 was phosphorylated at low levels only on
serine residues and IL-4 induced phosphorylation on both tyrosine and
serine residues (Fig. 5B). No phosphorylation on threonine
residues was detected. CD40 engagement did not have any marked effect
on phosphorylation of STAT6. Also, pretreatment of Daudi cells with
SB202190 did not inhibit tyrosine or serine phosphorylation of STAT6.
To confirm that phosphorylation of STAT6 was not affected by p38 MAPK,
part of the purified STAT6 protein was used for tryptic phosphopeptide
mapping (Fig. 5B). Two weakly phosphorylated peptides were
detected in nonstimulated cells. IL-4 stimulation enhanced the
phosphorylation of these peptides and induced three additional phosphopeptides. -CD40 treatment alone or in combination with IL-4
did not change the phosphorylation pattern of STAT6. However, in this
particular experiment a very faint phosphopeptide was induced by
-CD40, which was identified by the hot-sequencing method and
mutagenesis to correspond to the tyrosine 641 phosphopeptide (data not
shown). Previously longer -CD40 treatment (60 min) has been reported
to induce the tyrosine phosphorylation of STAT6 (39). Notably, in our
experiments neither CD23 expression on Ramos cells nor
STAT6-dependent reporter activities were stimulated via
CD40. In two subsequent experiments we were unable to reproduce the
induction of Tyr641 phosphorylation by -CD40 treatment.
SB202190 treatment did not change the phosphopeptide pattern of STAT6,
and there were no consistent changes in the relative intensities of
individual phosphopeptides. Thus, our results indicate that p38 MAPK
does not mediate the phosphorylation of STAT6.
p38 MAPK Regulates Directly the Transactivation Potential of STAT6
Transactivation Domain--
The findings that phosphorylation of STAT6
was not regulated by p38 MAPK lead us to consider the possibility that
p38 MAPK might affect the transactivation potential of STAT6. A fusion construct containing the yeast GAL4 DNA-binding domain and the TAD of
STAT6 (GAL4-STAT6TAD) was used to directly test this possibility. The
GAL4-STAT6 fusion construct has been shown to be constitutively active
and to bind DNA independently of extracellular stimuli (30).
GAL4-STAT6TAD and GAL4-binding sites containing reporter constructs
were transfected into Daudi B cells together with the dominant negative
form of p38 MAPK (p38AF), wild type p38 MAPK (p38wt), or empty
pSG5 plasmid DNA (sg5). Co-transfection of p38AF and SB202190 (10 µM) treatment diminished the reporter activity ~50-80%, whereas expression of p38wt resulted in enhancement of gene activation (Fig. 6A).
SB202190 treatment or expression of p38wt and p38AF constructs had no
effect on the control GAL4 construct in B cells (data not shown).

View larger version (11K):
[in this window]
[in a new window]
|
Fig. 6.
p38 MAPK regulates the TAD of STAT6.
A, Daudi B cells were transfected by electroporation with
GAL4-RE (8.0 µg), EBB- -galactosidase (8.0 µg), dominant
negative p38 MAPK (p38AF, 12 µg), and wild type p38 MAPK
(p38wt, 4 µg) as indicated. pSG5 plasmid (sg5) was used to make DNA
amounts equal. Two hours after transfection cells were left untreated
(black bars) or treated with SB202190 (10 µM)
(open bars) for 24 h as indicated. B, HepG2
cells were transfected as indicated with 0.5-3.0 µg of GAL4-RE,
CMV- -galactosidase, GAL4-STAT6TAD, p38 MAPK (p38wt), MKK6b(E),
and pSG5 plasmids by using the calcium phosphate coprecipitation
method. Cells were lysed 48 h after transfection. The luciferase
activities were normalized against -galactosidase values and
pSG5-transfected cells were given an arbitrary value of 100, and the
other values are shown in proportion to this as percentage of activity
(%). The means of three independent experiments with standard
deviations are shown.
|
|
Next we wanted to investigate whether the effects of p38 MAPK are
cell-type specific or whether it acts as an activator of STAT6TAD also
in nonhematopoietic cells. Therefore, HepG2 cells were transfected with
p38 MAPK plasmid alone or together with the constitutively active
form of its upstream activator mitogen-activated protein kinase kinase
6b (MKK6b(E)) (Fig. 6B). Co-transfection of both p38 MAPK
and MKK6b(E) further enhanced GAL4-STAT6TAD-mediated gene
activation. IL-4 treatment had no effect on STAT6TAD activity in Daudi
or HepG2 cells (data not shown). In conclusion, these results indicate
that p38 MAPK is regulating STAT6TAD-mediated transcriptional
activity in different cell types.
 |
DISCUSSION |
Cytokine-induced gene responses are controlled by integration of
signals from various signaling pathways on the promoter elements of
target genes. Activation of STAT6 is dependent on tyrosine phosphorylation, but IL-4-dependent gene responses are
modulated also through Ser/Thr kinase activity (2, 3, 13). In this study we provide new molecular insight into costimulatory signals for
IL-4-induced gene responses, and demonstrate that STAT6-mediated transcription is directly regulated by p38 MAPK.
Since CD40 provides a costimulatory signal for IL-4 and promotes p38
MAPK activation, we sought to investigate the role of p38 MAPK on
IL-4-induced gene responses. Our results demonstrate that p38 MAPK is
regulating the STAT6-dependent gene responses. Somewhat
surprisingly, inhibition of p38 MAPK, either by pharmacological inhibitors or by dominant negative p38 MAPK, inhibited both the basal
as well as the IL-4/CD40-induced expression of CD23. IL-4 did not
induce p38 MAPK activation in B cells, which is in accordance with
previous studies performed in other hematopoietic cells (40). CD40
engagement resulted in rapid activation of p38 MAPK in Daudi cells that
persisted for at least 6 h, and correlated directly with
enhancement of IL-4-induced reporter gene activation. In Ramos 2g6
cells CD40 induced only modest activation of p38 MAPK, which is in
accordance with the low level of -CD40 enhancement on CD23
expression in IL-4-treated Ramos cells. However, in all cell types
tested we observed basal activation of p38 MAPK, which was inhibited by
SB202190 treatment. The highest activity was observed in Ramos 2g6
cells that were initially characterized by their high IL-4-induced CD23
expression (41). Thus, our results suggest that the level of p38 MAPK
activity is critically regulating CD23 expression.
We dissected the role of p38 MAPK on different response elements on
IL-4-regulated promoter, and the STAT6-binding element was identified
as a direct target for p38 MAPK activity. The STAT6-RE was activated by
IL-4 stimulation and further stimulated in the presence of -CD40
whereas p38 MAPK inhibitors inhibited these activities. Our results
also showed that C/EBP activity was not regulated by p38 MAPK and
that C/EBP did not appear to be a substrate for p38 MAPK kinase
activity in B cells. These results also demonstrated that p38 MAPK is
not a general regulator of transcription and the effect of p38 MAPK is
STAT6-dependent. Interestingly, whereas C/EBP is
required for STAT6-mediated transactivation in HepG2 cells, this factor
is not required for STAT6 activity in B cells. This finding suggests
that B cells express either a transcription factor or a coactivator
that is critically required for STAT6-mediated transcription.
Several lines of evidence indicated that p38 MAPK is not directly
regulating the phosphorylation of STAT6. The SB202190 inhibitor did not
have any effect on tyrosine phosphorylation or DNA binding of STAT6.
Phosphoamino acid and phosphopeptide analysis indicated that CD40
engagement or SB202190 treatment are not regulating the phosphorylation
events of STAT6. In phosphoamino acid analysis or in phosphopeptide
mapping we could not detect any repeatable changes in the
phosphorylation pattern of STAT6 upon p38 MAPK activating ( -CD40) or
inactivating (SB202190) signals. However, the methodology used for
analysis of protein phosphorylation is not absolutely quantitative, and
thus we cannot strictly exclude the existence of a minor p38
MAPK-regulated phosphorylation event in STAT6. Furthermore, the TAD of
STAT6 does not contain the conserved MAPK Ser-phosphorylation motif
found in STAT1, STAT3, and STAT4. Taken together these results strongly
suggest that STAT6 is not a direct target for p38 MAPK kinase activity.
The kinase responsible for STAT6 phosphorylation is currently unknown
but the kinase is insensitive to H7, wortmannin, and SB202190 Ser/Thr
kinase inhibitors (13, 14). IL-4-induced serine phosphorylation has been reported to occur in the C-terminal TAD (14) but the exact Ser
residue(s) has not been identified. In STAT1 Ser727
phosphorylation regulates the interaction with transcriptional coregulators mini-chromosome maintenance 5 and BRCA1 (15, 17) and it is
possible that the phosphorylation-mediated increase in negative net
charge may promote protein interactions in STAT6TAD as well.
The reporter gene and phosphorylation studies suggested that the effect
of p38 MAPK is directed to the transcriptional activity of STAT6. In
accordance with this hypothesis, the STAT6TAD construct was directly
stimulated by p38 MAPK activation and inhibited by dominant negative
p38 MAPK or SB202190. These results would be consistent with a role for
p38 MAPK-mediated phosphorylation in regulation of interaction between
STAT6TAD and transcriptional coregulators. The effect of p38 MAPK on
NF- B bears some resemblance to our findings regarding regulation of
STAT6 activity (42). p38 MAPK has been shown to regulate the
transcriptional activity, but not the activation events of NF- B, by
inducing the phosphorylation of TATA-binding protein and thereby
facilitating the interaction between NF- B and TATA-binding protein.
We also investigated the possible role of p38 MAPK in regulation of the
TBP-STAT6 interaction, but p38 MAPK did not have any apparent effect on
TATA-binding protein phosphorylation in B cells (data not shown). The
IFN-regulated STAT1 signaling also shows analogy to our findings (19,
21, 22). IFN and IFN induce serine phosphorylation of STAT1
independently of p38 MAPK. However, p38 MAPK activity is required for
IFN /STAT1-mediated transcription of the interferon -activated
site and interferon-stimulated response element promoters. The exact
molecular mechanism by which STAT6 is connected to the basal
transcriptional machinery is currently poorly understood. Several
STATs, including STAT6, have been shown to interact with the general
coactivator p300/CBP, but currently there is no information that would
indicate that this interaction would be regulated by serine
phosphorylation (43). However, it is likely that other transcriptional
coregulators for STAT6 will be identified and p38 MAPK could be
involved in regulation of these functional interactions. Furthermore,
it is possible that in addition to the effects on transcriptional
activation of STAT6, p38 MAPK may also regulate transcription by
modulation of histone phosphorylation by the downstream kinase MSK-1
(44).
p38 MAPK is considered to be a proinflammatory regulator that is
activated via Th1 class cytokines as well as several stress-induced factors. Our results now demonstrate that p38 MAPK activity is also a
direct regulator of Th2 class cytokine-mediated responses and this
effect is targeted to STAT6-mediated transcription. In addition, our
results provide new molecular insight into CD40-mediated costimulatory
functions for IL-4-induced gene responses. Recently, several reports
have demonstrated an essential role for p38 MAPK in eosinophilic
inflammation (45, 46). Taken into account the effects of p38 MAPK on
both NF- B-, as well as on STAT6-mediated responses, modulators of
p38 MAPK kinase activity may prove to be effective drugs for allergic
diseases and asthma.
 |
ACKNOWLEDGEMENTS |
We thank Paula Kosonen and Dr. Anri
Tienhaara for technical assistance, Drs. B. Groner, V. M. Kähäri, J. Han, and T. Kallunki for kindly providing reagents.
 |
FOOTNOTES |
*
This work was supported by the Medical Research Fund of
Tampere University Hospital, the Academy of Finland, Tampere University Foundation, The Finnish Cultural Foundation, The Centenary Foundation of Kymi Corporation, The Finnish Cancer Foundation, The Tampere Tuberculosis Foundation, and the Sigrid Juselius Foundation.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Institute of
Medical Technology, University of Tampere, FIN-33014, Finland. Tel.: 358-3-215-7845; Fax: 358-3-215-7710; E-mail:
olli.silvennoinen@uta.fi.
Published, JBC Papers in Press, August 2, 2002, DOI 10.1074/jbc.M201427200
 |
ABBREVIATIONS |
The abbreviations used are:
IL-4, interleukin-4;
BRCA1, breast cancer susceptibility gene 1;
CBP/p300, CREB-binding protein/p300;
C/EBP , CCAAT/enhancer-binding protein
;
ERK, extracellular signal-regulated kinase;
Jak, Janus kinase;
MAPK, mitogen-activated protein kinase;
MKK6b, mitogen-activated
protein kinase kinase 6b;
STAT, signal transducer and activator of
transcription;
TAD, transactivation domain;
IFN, interferon;
FACS, fluorescence-activated cell sorter;
PE, phosphatidylethanolamine;
RE, response element.
 |
REFERENCES |
| 1.
|
Noelle, R. J.,
Roy, M.,
Shepherd, D. M.,
Stamenkovic, I.,
Ledbetter, J. A.,
and Aruffo, A.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
6550-6554[Abstract/Free Full Text]
|
| 2.
|
Nelms, K.,
Keegan, A. D.,
Zamorano, J.,
Ryan, J. J.,
and Paul, W. E.
(1999)
Annu. Rev. Immunol.
17,
701-738[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Warren, W. D.,
and Berton, M. T.
(1995)
J. Immunol.
155,
5637-5646[Abstract]
|
| 4.
|
Kuhn, R.,
Rajewsky, K.,
and Muller, W.
(1991)
Science
254,
707-710[Abstract/Free Full Text]
|
| 5.
|
Shimoda, K.,
van Deursen, J.,
Sangster, M. Y.,
Sarawar, S. R.,
Carson, R. T.,
Tripp, R. A.,
Chu, C.,
Quelle, F. W.,
Nosaka, T.,
Vignali, D. A.,
Doherty, P. C.,
Grosveld, G.,
Paul, W. E.,
and Ihle, J. N.
(1996)
Nature
380,
630-633[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Richards, M. L.,
and Katz, D. H.
(1997)
J. Immunol.
158,
263-272[Abstract]
|
| 7.
|
Gupta, S.,
Jiang, M.,
Anthony, A.,
and Pernis, A. B.
(1999)
J. Exp. Med.
190,
1837-1848[Abstract/Free Full Text]
|
| 8.
|
Brady, K.,
Fitzgerald, S.,
Ingvarsson, S.,
Borrebaeck, C. A.,
and Moynagh, P. N.
(2001)
Biochem. Biophys. Res. Commun.
289,
276-281[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Iciek, L. A.,
Delphin, S. A.,
and Stavnezer, J.
(1997)
J. Immunol.
158,
4769-4779[Abstract]
|
| 10.
|
Shen, C. H.,
and Stavnezer, J.
(1998)
Mol. Cell. Biol.
18,
3395-3404[Abstract/Free Full Text]
|
| 11.
|
Mikita, T.,
Kurama, M.,
and Schindler, U.
(1998)
J. Immunol.
161,
1822-1828[Abstract/Free Full Text]
|
| 12.
|
Decker, T.,
and Kovarik, P.
(2000)
Oncogene
19,
2628-2637[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Pesu, M.,
Takaluoma, K.,
Aittomaki, S.,
Lagerstedt, A.,
Saksela, K.,
Kovanen, P. E.,
and Silvennoinen, O.
(2000)
Blood
95,
494-502[Abstract/Free Full Text]
|
| 14.
|
Wick, K. R.,
and Berton, M. T.
(2000)
Mol. Immunol.
37,
641-652[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Zhang, J. J.,
Zhao, Y.,
Chait, B. T.,
Lathem, W. W.,
Ritzi, M.,
Knippers, R.,
and Darnell, J. E.
(1998)
EMBO J.
17,
6963-6971[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Kovarik, P.,
Mangold, M.,
Ramsauer, K.,
Heidari, H.,
Steinborn, R.,
Zotter, A.,
Levy, D. E.,
Muller, M.,
and Decker, T.
(2001)
EMBO J.
20,
91-100[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Ouchi, T.,
Lee, S. W.,
Ouchi, M.,
Aaronson, S. A.,
and Horvath, C. M.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
5208-5213[Abstract/Free Full Text]
|
| 18.
|
Chung, J.,
Uchida, E.,
Grammer, T. C.,
and Blenis, J.
(1997)
Mol. Cell. Biol.
17,
6508-6516[Abstract]
|
| 19.
|
Kovarik, P.,
Stoiber, D.,
Eyers, P. A.,
Menghini, R.,
Neininger, A.,
Gaestel, M.,
Cohen, P.,
and Decker, T.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
13956-13961[Abstract/Free Full Text]
|
| 20.
|
Visconti, R.,
Gadina, M.,
Chiariello, M.,
Chen, E. H.,
Stancato, L. F.,
Gutkind, J. S.,
and O'Shea, J. J.
(2000)
Blood
96,
1844-1852[Abstract/Free Full Text]
|
| 21.
|
Uddin, S.,
Majchrzak, B.,
Woodson, J.,
Arunkumar, P.,
Alsayed, Y.,
Pine, R.,
Young, P. R.,
Fish, E. N.,
and Platanias, L. C.
(1999)
J. Biol. Chem.
274,
30127-30131[Abstract/Free Full Text]
|
| 22.
|
Uddin, S.,
Lekmine, F.,
Sharma, N.,
Majchrzak, B.,
Mayer, I.,
Young, P. R.,
Bokoch, G. M.,
Fish, E. N.,
and Platanias, L. C.
(2000)
J. Biol. Chem.
275,
27634-27640[Abstract/Free Full Text]
|
| 23.
|
Zauberman, A.,
Zipori, D.,
Krupsky, M.,
and Ben-Levy, R.
(1999)
Oncogene
18,
3886-3893[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Faris, M.,
Gaskin, F.,
Parsons, J. T.,
and Fu, S. M.
(1994)
J. Exp. Med.
179,
1923-1931[Abstract/Free Full Text]
|
| 25.
|
Hanissian, S. H.,
and Geha, R. S.
(1997)
Immunity
6,
379-387[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Sutherland, C. L.,
Heath, A. W.,
Pelech, S. L.,
Young, P. R.,
and Gold, M. R.
(1996)
J. Immunol.
157,
3381-3390[Abstract]
|
| 27.
|
Berberich, I.,
Shu, G. L.,
and Clark, E. A.
(1994)
J. Immunol.
153,
4357-4366[Abstract]
|
| 28.
|
Yamashita, Y.,
Watanabe, S.,
Miyazato, A.,
Ohya, K.,
Ikeda, U.,
Shimada, K.,
Komatsu, N.,
Hatake, K.,
Miura, Y.,
Ozawa, K.,
and Mano, H.
(1998)
Blood
91,
1496-1507[Abstract/Free Full Text]
|
| 29.
|
Saharinen, P.,
Ekman, N.,
Sarvas, K.,
Parker, P.,
Alitalo, K.,
and Silvennoinen, O.
(1997)
Blood
90,
4341-4353[Abstract/Free Full Text]
|
| 30.
|
Moriggl, R.,
Berchtold, S.,
Friedrich, K.,
Standke, G. J.,
Kammer, W.,
Heim, M.,
Wissler, M.,
Stocklin, E.,
Gouilleux, F.,
and Groner, B.
(1997)
Mol. Cell. Biol.
17,
3663-3678[Abstract]
|
| 31.
|
Raingeaud, J.,
Whitmarsh, A. J.,
Barrett, T.,
Derijard, B.,
and Davis, R. J.
(1996)
Mol. Cell. Biol.
16,
1247-1255[Abstract]
|
| 32.
|
Boyle, W. J.,
van der Geer, P.,
and Hunter, T.
(1991)
Methods Enzymol.
201,
110-149[Medline]
[Order article via Infotrieve]
|
| 33.
|
Jabara, H. H., Fu, S. M.,
Geha, R. S.,
and Vercelli, D.
(1990)
J. Exp. Med.
172,
1861-1864[Abstract/Free Full Text]
|
| 34.
|
Paterson, R. L.,
Lack, G.,
Domenico, J. M.,
Delespesse, G.,
Leung, D. Y.,
Finkel, T. H.,
and Gelfand, E. W.
(1996)
Eur. J. Immunol.
26,
1979-1984[Medline]
[Order article via Infotrieve]
|
| 35.
|
Davies, S. P.,
Reddy, H.,
Caivano, M.,
and Cohen, P.
(2000)
Biochem. J.
351,
95-105[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Craxton, A.,
Shu, G.,
Graves, J. D.,
Saklatvala, J.,
Krebs, E. G.,
and Clark, E. A.
(1998)
J. Immunol.
161,
3225-3236[Abstract/Free Full Text]
|
| 37.
|
Mikita, T.,
Campbell, D., Wu, P.,
Williamson, K.,
and Schindler, U.
(1996)
Mol. Cell. Biol.
16,
5811-5820[Abstract]
|
| 38.
|
Buck, M.,
Poli, V.,
van der Geer, P.,
Chojkier, M.,
and Hunter, T.
(1999)
Mol. Cell
4,
1087-1092[CrossRef][Medline]
[Order article via Infotrieve]
|
| 39.
|
Karras, J. G.,
Wang, Z.,
Huo, L.,
Frank, D. A.,
and Rothstein, T. L.
(1997)
J. Immunol.
159,
4350-4355[Abstract]
|
| 40.
|
Foltz, I. N.,
Lee, J. C.,
Young, P. R.,
and Schrader, J. W.
(1997)
J. Biol. Chem.
272,
3296-3301[Abstract/Free Full Text]
|
| 41.
|
Siegel, J. P.,
and Mostowski, H. S.
(1990)
J. Immunol. Methods
132,
287-295[CrossRef][Medline]
[Order article via Infotrieve]
|
| 42.
|
Carter, A. B.,
Knudtson, K. L.,
Monick, M. M.,
and Hunninghake, G. W.
(1999)
J. Biol. Chem.
274,
30858-30863[Abstract/Free Full Text]
|
| 43.
|
McDonald, C.,
and Reich, N. C.
(1999)
J. Interferon Cytokine Res.
19,
711-722[CrossRef][Medline]
[Order article via Infotrieve]
|
| 44.
|
Thomson, S.,
Clayton, A. L.,
Hazzalin, C. A.,
Rose, S.,
Barratt, M. J.,
and Mahadevan, L. C.
(1999)
EMBO J.
18,
4779-4793[CrossRef][Medline]
[Order article via Infotrieve]
|
| 45.
|
Underwood, D. C.,
Osborn, R. R.,
Kotzer, C. J.,
Adams, J. L.,
Lee, J. C.,
Webb, E. F.,
Carpenter, D. C.,
Bochnowicz, S.,
Thomas, H. C.,
Hay, D. W.,
and Griswold, D. E.
(2000)
J. Pharmacol. Exp. Ther.
293,
281-288[Abstract/Free Full Text]
|
| 46.
|
Birrell, M.,
Hele, D.,
McCluskie, K.,
Webber, S.,
Foster, M.,
and Belvisi, M. G.
(2000)
Eur. Respir. J.
16,
947-950[Abstract]
|
| 47.
|
Tanaka, M.,
Gupta, R.,
and Mayer, B. J.
(1995)
Mol. Cell. Biol.
15,
6829-6837[Abstract]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
B. Schaljo, F. Kratochvill, N. Gratz, I. Sadzak, I. Sauer, M. Hammer, C. Vogl, B. Strobl, M. Muller, P. J. Blackshear, et al.
Tristetraprolin Is Required for Full Anti-Inflammatory Response of Murine Macrophages to IL-10
J. Immunol.,
July 15, 2009;
183(2):
1197 - 1206.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Zhang, S. Rosenberg, F. J. Coffey, Y.-W. He, T. Manser, R. R. Hardy, and J. Zhang
A Role for cFLIP in B Cell Proliferation and Stress MAPK Regulation
J. Immunol.,
January 1, 2009;
182(1):
207 - 215.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Pongratz, J. W. McAlees, D. H. Conrad, R. S. Erbe, K. M. Haas, and V. M. Sanders
The Level of IgE Produced by a B Cell Is Regulated by Norepinephrine in a p38 MAPK- and CD23-Dependent Manner.
J. Immunol.,
September 1, 2006;
177(5):
2926 - 2938.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Yamada, K. Zhang, A. Yamada, D. Zhu, and A. Saxon
B Lymphocyte Stimulator Activates p38 Mitogen-Activated Protein Kinase in Human Ig Class Switch Recombination
Am. J. Respir. Cell Mol. Biol.,
May 1, 2005;
32(5):
388 - 394.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Canfield, Y. Lee, A. Schroder, and P. Rothman
Cutting Edge: IL-4 Induces Suppressor of Cytokine Signaling-3 Expression in B Cells by a Mechanism Dependent on Activation of p38 MAPK
J. Immunol.,
March 1, 2005;
174(5):
2494 - 2498.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Q. Peng, T. Matsuda, and S. J. Hirst
Signaling Pathways Regulating Interleukin-13-stimulated Chemokine Release from Airway Smooth Muscle
Am. J. Respir. Crit. Care Med.,
March 1, 2004;
169(5):
596 - 603.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Xu, A. Bhattacharjee, B. Roy, H.-M. Xu, D. Anthony, D. A. Frank, G. M. Feldman, and M. K. Cathcart
Interleukin-13 Induction of 15-Lipoxygenase Gene Expression Requires p38 Mitogen-Activated Protein Kinase-Mediated Serine 727 Phosphorylation of Stat1 and Stat3
Mol. Cell. Biol.,
June 1, 2003;
23(11):
3918 - 3928.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|